EUCTR2011-000978-53-GB进行中（未招募）不适用
Randomised, double-blind, placebo-controlled Phase II proof-of-concept study of APD515 solution for oromucosal and oral administration for relief of xerostomia in patients with cancer - Phase II PoC study of APD515 v1.1
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Aged = 18 years
- •2.Able and willing to give written informed consent.
- •3.Confirmed primary neoplasm at any site (apart from non-melanoma skin cancers), for which first-line cytotoxic therapy has been completed more than one month prior to study entry. Ongoing palliative, hormonal, cytostatic or targeted” (e.g., monoclonal antibody, tyrosine kinase inhibitor, etc) therapy is permitted, provided that the risk of oral mucositis in the subject is not judged to be significant.
- •4.Subjective complaint of dry mouth, ongoing for at least two weeks prior to study entry.
- •5.Capacity for salivary stimulation, as demonstrated by stimulated whole saliva flow rate > unstimulated whole saliva flow rate.
- •6.Karnofsky performance score = 60% or ECOG performance status = 2.
- •7.Adequate renal and hepatic function and hydration status:
- •Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 5 x upper limit normal (ULN);
- •Serum urea < 1.5 x ULN and serum urea:creatinine ratio < 100 (where urea and creatinine expressed in the same units);
- •Plasma sodium = ULN.
- •8.Adequate haematological function:
- •Haemoglobin = 9 g/dL;
- •White blood count = 1.0 x 10^9/L;
- •Platelet count = 50 x 10^9/L.
- •9.Willing to use an effective form of contraception during the study and for a period of fourteen days afterwards:
- •For male subjects adequate contraception may be achieved through abstinence from sexual intercourse or use of a double barrier method of contraception.
- •For female subjects adequate contraception may be achieved through abstinence from sexual intercourse, surgical sterilization (of subject or partner), by being post-menopausal (no spontaneous menstrual period for at least one year), or by the use of a double barrier method of contraception.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 0
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •1.Confirmed diagnosis of Sjögren’s syndrome.
- •2.Prior radiotherapy for head & neck cancer, or other substantial doses of radiation delivered to the area of the mouth or salivary glands.
- •3.Significant, symptomatic disease of the oral cavity, including oral candidosis or oral mucositis.
- •4.Allergy to active ingredient or any of the excipients of APD515.
- •5.Use of oral or topical (including ocular) pilocarpine or cevimeline in the two weeks prior to enrolment.
- •6.Concomitant use of procainamide, quinidine or ganglionic blocking agents such as mecamylamine, pentolinium and trimethaphan.
- •7.Intestinal or urinary obstruction.
- •8.Myocardial infarction or intestinal anastomosis within the previous 6 months.
- •9.Participation in an investigational drug or device study within 1 month prior to study entry.
- •10.For female subjects only, a positive pregnancy test.
- •11.Female subjects who are lactating.
- •12.Any condition or disease detected during the medical interview/physical examination that would render the subject unsuitable for the study, place the subject at undue risk or interfere with the ability of the subject to complete the study in the opinion of the Investigator.
研究者
相似试验
进行中（未招募）
不适用
Randomised, double-blind, placebo-controlled Phase II proof-of-concept study of APD515 solution for oromucosal and oral administration for relief of xerostomia in patients with cancer - Phase II PoC study of APD515 v1.2XerostomiaMedDRA version: 14.0Level: LLTClassification code 10048223Term: XerostomiaSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2011-000978-53-DKAcacia Pharma Ltd30
已完成
1 期
A Phase I study of orally inhaled PB01 in healthy male participants following single and repeat administration.ACTRN12615000984594Paranta Biosciences Ltd56
进行中（未招募）
2 期
Randomized, double-blind, placebo controlled Phase II study to evaluate the efficacy and safety of Sorafenib treatment in patients with advanced (recurrent, persistent and/or metastasizing) medullary thyroid carcinoma (SUMMIT).C73Malignant neoplasm of thyroid glandDRKS00004455EANM Forschungs GmbH/ EANM Research Ltd.
尚未招募
2 期
Randomised, double-blind, placebo controlled phase II study of the efficacy of Phospha-E biomarkers of inflammation, in patients with metabolic syndrome and mild to moderate hyperlipidemia.Metabolic SyndromeMetabolic and Endocrine - Other metabolic and endocrine disordersACTRN12607000343404Phosphagenics Limited160
进行中（未招募）
不适用
Randomized, placebo-controlled, double-blind Phase 1b/2 study of U3-1287 (AMG 888) in combination with erlotinib in EGFR treatment naïve subjects with advanced non-small cell lung cancer (NSCLC) who have progressed on at least one prior chemotherapy.EUCTR2010-021082-74-ITDAIICHI SANKYO PHARMA DEVELOPMENT210